Moving Past the “Carrier” Perspective: Examining X-linked CGD in Heterozygous Females
CIS Lunch Symposium
Meeting Details
Thursday, May 2, 2024
12:30 PM - 1:30 PM CT
Renaissance Minneapolis Hotel, The Depot
Room: Great Hall
Minneapolis, MN
 | ||||
Approved Uses and Important Safety Information INDICATIONS AND USAGE
ACTIMMUNE® (Interferon gamma-1b) is indicated: • For reducing the frequency and severity of serious infections associated with chronic granulomatous
disease
• For delaying time to disease progression in patients with severe, malignant osteopetrosis IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
• In patients who develop or have known hypersensitivity to interferon gamma-1b, E. coli-derived products,
or any component of the product
Please see Full Prescribing Information and additional safety information at ACTIMMUNEhcp.com.
Please note, you must also be registered for the CIS 2024 Annual Meeting in order to attend this symposium. REPORTING DISCLOSURE: All meal participants will be required to sign in at this event. As required by the federal Sunshine Act and other similar state laws, the cost of the meal provided to you will be publicly reported. If you want to attend the program without your information reported, you may opt out of the meal. This is a non-CME program sponsored by Amgen intended for health care professionals. Please note that Amgen adheres to the principles set forth in the PhRMA Code on Interactions with Health Care Professionals. All program functions are for invited guests only. Spouses and others, including office staff or other family members, may not attend. This symposium, content and views expressed therein are those of Amgen and not of CIS. © 2024 Horizon Therapeutics Limited P-ACT-US-00257 02/24 |
